BPC-157 vs Dihexa

BPC-157 and Dihexa are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.

Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.

Dihexa (PNB-0408) is a synthetic small molecule derived from angiotensin IV, developed at Washington State University by the Harding lab. It is a hepatocyte growth factor (HGF) mimetic that activates HGF/c-Met signaling in the brain, promoting synaptogenesis, neuroplasticity, and neuronal survival. Unlike large HGF proteins, Dihexa has good oral bioavailability and crosses the blood-brain barrier. In APP/PS1 Alzheimer's model mice, Dihexa activated the PI3K/AKT pathway, reduced neuroinflammation, and rescued cognitive impairment. It has also shown promise for peripheral nerve regeneration and protection against chemical ototoxicity. No human clinical trials exist.

Key claims: Rescues cognitive impairment in Alzheimer's model; Promotes peripheral nerve regeneration; Protects against chemical ototoxicity.

These peptides target different research areas. BPC-157 focuses on Injury Recovery, Gut Health, while Dihexa targets Cognitive Enhancement.

BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.

Dihexa: No human safety data exists whatsoever Short-duration animal studies report no apparent toxicity at research dosages Potent HGF/c-Met activation raises theoretical oncological concerns (c-Met pathway involved in tumor progression)